Morpholines
"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D009025
|
MeSH Number(s) |
D03.383.533.640
|
Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in UAMS Profiles by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 1 | 1 | 2 | 2023 | 0 | 1 | 1 | 2021 | 2 | 0 | 2 | 2020 | 0 | 1 | 1 | 2018 | 0 | 2 | 2 | 2017 | 1 | 3 | 4 | 2016 | 1 | 4 | 5 | 2015 | 1 | 0 | 1 | 2014 | 0 | 2 | 2 | 2013 | 1 | 0 | 1 | 2012 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 | 2010 | 2 | 0 | 2 | 2009 | 0 | 1 | 1 | 2008 | 1 | 3 | 4 | 2007 | 0 | 1 | 1 | 2006 | 0 | 2 | 2 | 2005 | 2 | 1 | 3 | 2004 | 1 | 2 | 3 | 2003 | 1 | 0 | 1 | 2002 | 0 | 3 | 3 | 2001 | 0 | 2 | 2 | 2000 | 1 | 0 | 1 | 1999 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Morpholines" by people in Profiles over the past ten years.
-
Waldrip ZJ, Acharya B, Armstrong D, Hanafi M, Rainwater RR, Amole S, Fulmer M, Azevedo-Pouly AC, Burns A, Burdine L, Frett B, Burdine MS. Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441. Sci Rep. 2024 08 28; 14(1):19999.
-
Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):762-769.
-
Park Y, Jung J, Jeong S, van Ee A, Garza LA, Jang M, Kim D, Park J. Reversine enhances skin barrier functions by suppressing the IL-4- and IL-13-mediated STAT6 pathway. J Dermatol Sci. 2023 08; 111(2):71-73.
-
Shoeib AM, Yarbrough AL, Ford BM, Franks LN, Urbaniak A, Hensley LL, Benson LN, Mu S, Radominska-Pandya A, Prather PL. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sci. 2021 Nov 15; 285:119993.
-
Harrison DK, Waldrip ZJ, Burdine L, Shalin SC, Burdine MS. DNA-PKcs Inhibition Extends Allogeneic Skin Graft Survival. Transplantation. 2021 03 01; 105(3):540-549.
-
Ord??ez PE, Mery DE, Sharma KK, Nemu S, Reynolds WF, Enriquez RG, Burns DC, Malag?n O, Jones DE, Guzman ML, Compadre CM. Synthesis, Crystallography, and Anti-Leukemic Activity of the Amino Adducts of Dehydroleucodine. Molecules. 2020 Oct 20; 25(20).
-
Wen PY, Rodon JA, Mason W, Beck JT, DeGroot J, Donnet V, Mills D, El-Hashimy M, Rosenthal M. Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ESMO Open. 2020 07; 5(4).
-
Franks LN, Ford BM, Fujiwara T, Zhao H, Prather PL. The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicol Appl Pharmacol. 2018 08 15; 353:31-42.
-
Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clin Cancer Res. 2018 08 15; 24(16):3928-3940.
-
Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, Rabin N, Kurman M, Novak B, Shiraishi N, Nakashima D, Akinaga S, Yong K. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br J Cancer. 2017 Oct 24; 117(9):1295-1302.
-
Hong WC, Yano H, Hiranita T, Chin FT, McCurdy CR, Su TP, Amara SG, Katz JL. The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. J Biol Chem. 2017 07 07; 292(27):11250-11261.
-
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518.
-
Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav Neurosci. 2017; 32:249-262.
-
Wilbur MB, Birrer MJ, Spriggs DR. CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):177-9.
-
Pinheiro BS, Lemos C, Neutzling Kaufmann F, Marques JM, da Silva-Santos CS, Carvalho E, Mackie K, Rodrigues RJ, Cunha RA, K?falvi A. Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin. Brain Res Bull. 2016 06; 124:222-30.
-
Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, Lau S, Poveda A, Gonz?lez-Mart?n A, Muller C, Muro K, Pierce K, Suzuki M, Vermette J, Oza A. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol. 2016 Jul; 142(1):62-69.
-
Katz JL, Hiranita T, Kopajtic TA, Rice KC, Mesangeau C, Narayanan S, Abdelazeem AH, McCurdy CR. Blockade of Cocaine or s Receptor Agonist Self Administration by Subtype-Selective s Receptor Antagonists. J Pharmacol Exp Ther. 2016 07; 358(1):109-24.
-
Maroso M, Szabo GG, Kim HK, Alexander A, Bui AD, Lee SH, Lutz B, Soltesz I. Cannabinoid Control of Learning and Memory through HCN Channels. Neuron. 2016 Mar 02; 89(5):1059-73.
-
Tai S, Nikas SP, Shukla VG, Vemuri K, Makriyannis A, J?rbe TU. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist. Psychopharmacology (Berl). 2015 Aug; 232(15):2751-61.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|